LINC 2023: Late-breaking Science Video Collection
Published: 20 June 2023
-
Views:
794
-
Likes:
7
-
Views:
794
-
Likes:
7
-
Up Next -
6m 6sPart 1 | Session 8 Improving Clinical Outcomes in Infrapopliteal Lesions With Cre8™ BTK -
8m 56sPart 1 | Session 9 LIFE-BTK: Esprit BTK System in Narrowed Infrapopliteal Lesions
-
5m 2sPart 1 | Session 1 AVPAS: Lutonix AV Post-Approval Study Scott O Trerotola
-
5m 18sPart 1 | Session 2 The ELEGANCE Registry: Ranger DCB In Under-Represented Groups Marianne Brodmann
-
4m 51sPart 1 | Session 3 RANGER II SFA: 3 Year Patency and 4 Year Clinical Safety Marianne Brodmann
-
4m 48sPart 1 | Session 4 IN.PACT AV ACCESS: Outcomes to Date Matteo Tozzi
-
8m 14sPart 1 | Session 5 TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes Koen Deloose
-
7m 13sPart 1 | Session 6 POPCORN Registry: DCB Treatment for Peripheral Artery Disease Yoshimitsu Soga
Overview
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
Expert Interviews
Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.
About the episode
LINC 23 - We are joined by Dr Michel Bosiers (Inselspital Bern, CH) to discuss the findings of the MOTIV BTS BTK trial, which studied the immediate and long-term clinical outcomes of the MOTIV™ Bioresorbable Scaffold in patients with peripheral artery disease and/or critical limb ischemia.
The MOTIV™ scaffold is a novel device made from Tyrocore™, with thin struts to promote vessel healing and maintain radial strength. 60 patients were enrolled in the trial who were followed up to 36 months after implantation of the MOTIV™ device. Data revealed at LINC 2023 shows a 99% technical success rate and an 88.3% rate of vessel patency.
Questions:
- What was the objective of this trial?
- Tell us more about the MOTIV Scaffold, and its unique features.
- What was the patient population and study design?
- What was the key data released at LINC 2023?
- How should the findings of this trial impact both future research and clinical practice?
Recorded remotely from Bern, 2023.
Editor: Jordan Rance
Video Specialist: Dan Brent
Faculty Biographies
Michel Bosiers
Senior Consultant
Dr Michel Bosiers is the Senior Consultant at the University Hospital Bern. He is co-founder of Vascupedia. His areas of interest include vascular innovation, peripheral vascular disease and endovascular access.
Comments